# Brent A Appleton

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7725050/publications.pdf

Version: 2024-02-01

| 30 | 2,629 | 279798 | 454955 |
|---|---|---|---|
| papers | citations | 23 h-index | 30 g-index |

| 30 | 30 | 30 | 3957 |
|---|---|---|---|
| all docs | docs citations | times ranked | citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | A Specificity Map for the PDZ Domain Family. PLoS Biology, 2008, 6, e239. | 5.6 | 410 |
| 2 | Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site. Science, 2009, 323, 1610-1614. | 12.6 | 342 |
| 3 | Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding. EMBO Journal, 2007, 26, 4902-4912. | 7.8 | 192 |
| 4 | Structure of IL-33 and Its Interaction with the ST2 and IL-1RAcP Receptorsâ€"Insight into Heterotrimeric IL-1 Signaling Complexes. Structure, 2009, 17, 1398-1410. | 3.3 | 174 |
| 5 | Comprehensive Analysis of the Factors Contributing to the Stability and Solubility of Autonomous Human VH Domains. Journal of Biological Chemistry, 2008, 283, 3639-3654. | 3.4 | 157 |
| 6 | Inhibition of Wnt signaling by Dishevelled PDZ peptides. Nature Chemical Biology, 2009, 5, 217-219. | 8.0 | 143 |
| 7 | A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients. Cancer Research, 2011, 71, 5255-5264. | 0.9 | 109 |
| 8 | The Crystal Structure of Murine Coronin-1: A Regulator of Actin Cytoskeletal Dynamics in Lymphocytes. Structure, 2006, 14, 87-96. | 3.3 | 106 |
| 9 | The Cytomegalovirus DNA Polymerase Subunit UL44 Forms a C Clamp-Shaped Dimer. Molecular Cell, 2004, 15, 233-244. | 9.7 | 96 |
| 10 | Convergent and Divergent Ligand Specificity among PDZ Domains of the LAP and Zonula Occludens (ZO) Families. Journal of Biological Chemistry, 2006, 281, 22299-22311. | 3.4 | 94 |
| 11 | Structural and functional analysis of the PDZ domains of human HtrA1 and HtrA3. Protein Science, 2007, 16, 2454-2471. | 7.6 | 86 |
| 12 | A Structural Portrait of the PDZ Domain Family. Journal of Molecular Biology, 2014, 426, 3509-3519. | 4.2 | 71 |
| 13 | Residues of Human Cytomegalovirus DNA Polymerase Catalytic Subunit UL54 That Are Necessary and Sufficient for Interaction with the Accessory Protein UL44. Journal of Virology, 2004, 78, 158-167. | 3.4 | 70 |
| 14 | Comparative Structural Analysis of the Erbin PDZ Domain and the First PDZ Domain of ZO-1. Journal of Biological Chemistry, 2006, 281, 22312-22320. | 3.4 | 70 |
| 15 | Novel Potent and Selective Inhibitors of p90 Ribosomal S6 Kinase Reveal the Heterogeneity of RSK Function in MAPK-Driven Cancers. Molecular Cancer Research, 2014, 12, 803-812. | 3.4 | 60 |
| 16 | Specific Residues in the Connector Loop of the Human Cytomegalovirus DNA Polymerase Accessory Protein UL44 Are Crucial for Interaction with the UL54 Catalytic Subunit. Journal of Virology, 2004, 78, 9084-9092. | 3.4 | 58 |
| 17 | Crystal Structure of the Cytomegalovirus DNA Polymerase Subunit UL44 in Complex with the C Terminus from the Catalytic Subunit. Journal of Biological Chemistry, 2006, 281, 5224-5232. | 3.4 | 56 |
| 18 | Structural and functional analysis of the ligand specificity of the HtrA2/Omi PDZ domain. Protein Science, 2007, 16, 1738-1750. | 7.6 | 51 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Discovery of Potent and Selective RSK Inhibitors as Biological Probes. Journal of Medicinal Chemistry, 2015, 58, 6766-6783. | 6.4 | 50 |
| 20 | Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic Melanoma. ACS Medicinal Chemistry Letters, 2015, 6, 961-965. | 2.8 | 37 |
| 21 | Design and Discovery of N-(2-Methyl-5â€²-morpholino-6â€²-((tetrahydro-2H-pyran-4-yl)oxy)-[3,3â€²-bipyridin]-5-yl)-3-(trifluoromethyl)benzamide (RAF709): A Potent, Selective, and Efficacious RAF Inhibitor Targeting RAS Mutant Cancers. Journal of Medicinal Chemistry, 2017, 60, 4869-4881. | 6.4 | 37 |
| 22 | Design and Discovery of N-(3-(2-(2-Hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methylphenyl)-2-(trifluoromethyl)isonicotinamide, a Selective, Efficacious, and Well-Tolerated RAF Inhibitor Targeting RAS Mutant Cancers: The Path to the Clinic. Journal of Medicinal Chemistry, 2020, 63, 2013-2027. | 6.4 | 27 |
| 23 | Discovery and Optimization of Phosphopantetheine Adenylyltransferase Inhibitors with Gram-Negative Antibacterial Activity. Journal of Medicinal Chemistry, 2018, 61, 3325-3349. | 6.4 | 26 |
| 24 | Fragment-Based Drug Discovery of Inhibitors of Phosphopantetheine Adenylyltransferase from Gram-Negative Bacteria. Journal of Medicinal Chemistry, 2018, 61, 3309-3324. | 6.4 | 24 |
| 25 | 2-Amino-7-substituted benzoxazole analogs as potent RSK2 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 1592-1596. | 2.2 | 21 |
| 26 | Discovery of a Selective and Potent Inhibitor of Mitogen-Activated Protein Kinase-Interacting Kinases 1 and 2 (MNK1/2) Utilizing Structure-Based Drug Design. Journal of Medicinal Chemistry, 2016, 59, 3034-3045. | 6.4 | 20 |
| 27 | Discovery of the 1,7-diazacarbazole class of inhibitors of checkpoint kinase 1. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 5704-5709. | 2.2 | 14 |
| 28 | Design and synthesis of potent RSK inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 3197-3201. | 2.2 | 10 |
| 29 | Mathematical and Structural Characterization of Strong Nonadditive Structureâ€“Activity Relationship Caused by Protein Conformational Changes. Journal of Medicinal Chemistry, 2018, 61, 7754-7766. | 6.4 | 10 |
| 30 | Imidazo[1,2- a ]pyridin-6-yl-benzamide analogs as potent RAF inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 5221-5224. | 2.2 | 8 |